EBITDA: Income before interest, taxes, depreciation and amortization.
Satellos Bioscience Inc. (MSLE) had EBITDA of $-26.45M for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
-- |
|
$-24.87M |
|
-- |
|
-- |
|
$26.46M |
|
$-26.46M |
|
$1.76M |
|
$-24.70M |
|
$-24.70M |
|
$-24.87M |
|
$-24.87M |
|
$-24.87M |
|
$-24.87M |
|
$-26.46M |
|
|
EBITDA |
$-26.45M |
14.60M |
|
14.60M |
|
$-1.70 |
|
$-1.70 |
|
| Balance Sheet Financials | |
$31.88M |
|
$0.01M |
|
$0.01M |
|
$31.89M |
|
$4.11M |
|
-- |
|
-- |
|
$4.11M |
|
$27.78M |
|
$27.78M |
|
$27.78M |
|
15.46M |
|
| Cash Flow Statement Financials | |
$-23.60M |
|
$-9.42M |
|
$2.24M |
|
$40.07M |
|
$9.80M |
|
$-30.27M |
|
$3.23M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
7.77 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-23.60M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-89.52% |
|
-89.52% |
|
-78.00% |
|
-89.52% |
|
$1.80 |
|
$-1.62 |
|
$-1.62 |
|